GHRP-6: The Complete Guide

GHRP-6 is the original synthetic growth-hormone-releasing peptide: His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, six amino acids with a C-terminal amide and two D-amino-acid substitutions (D-Trp at position 2, D-Phe at position 5) that confer protease resistance. Founding paper: Bowers CY, Momany FA, Reynolds GA, Hong A. Endocrinology 1984;114(5):1537-45 (PMID 6714155).

It's the parent scaffold of the family. GHRP-2 (pralmorelin), hexarelin, GHRP-1, and structurally related ghrelin-receptor agonists are all derived from it. The ancestry traces further back to weak GH-releasing Met-enkephalin analogs from the same Bowers lab (Momany & Bowers 1981, PMID 6109621); the final hexapeptide isn't a structural enkephalin, but it descends from those scaffolds via iterative conformational-energy design.

The unusual fact about GHRP-6: it predicted the existence of the natural hormone. The ghrelin receptor (GHS-R1a) was cloned in 1996 (Howard et al., Science, PMID 8688086) specifically because GHRP-6 and the small-molecule MK-677 needed a receptor. The endogenous ligand ghrelin was then discovered three years later (Kojima et al., Nature 1999, PMID 10604470). Few small-molecule pharmacology stories run in this order.

Regulatory status

• FDA, EMA: not approved. No NDA, no IND, not on the 503A bulks list. Research chemical only in the US.
• Japan: note that GHRP-2 (pralmorelin) — not GHRP-6 — was developed as a clinical GH-deficiency diagnostic. Don't conflate them.
• WADA 2026: prohibited at all times under S2.2 (Peptide Hormones, GHS / GHRP sub-class), in force 2026-01-01.
• DEA: not scheduled.

GHRP-6 acts on the Growth Hormone Secretagogue Receptor 1a (GHS-R1a), a class-A G-protein-coupled receptor on anterior-pituitary somatotrophs and hypothalamic neurons (arcuate nucleus, ventromedial and paraventricular nuclei), with lower density on heart, vasculature, immune cells, pancreas, and gut. Signaling runs through Gαq/11 to phospholipase C, generating IP₃ and diacylglycerol, mobilizing intracellular Ca²⁺, and driving calcium-dependent GH exocytosis (Herrington & Hille 1994, PMID 8070352).

This pathway is mechanistically distinct from the GHRH-receptor signaling used by sermorelin, tesamorelin, and CJC-1295 (class-B GPCR, Gαs → cAMP → PKA). Because the two pathways converge on the somatotroph through different second messengers, GHRH + GHRP synergy is robust in human acute provocation studies (Popovic 1994 PMID 8045963; Cordido 1996 PMID 8772550). Pairing GHRP-6 with a GHRH analog produces a larger GH pulse than either alone.

The full GH-release effect involves three components: direct pituitary stimulation on somatotrophs, hypothalamic mediation (GHRP-6-induced GH release is completely blocked in patients with hypothalamic-pituitary disconnection — Popovic 1995 PMID 7883854), and functional release-from-somatostatin-brake inferred from the GHRH+GHRP synergy data.

The appetite mechanism — GHRP-6's real differentiator

GHRP-6 binds GHS-R1a in the hypothalamic arcuate nucleus and ventromedial hypothalamus — the same loci where endogenous ghrelin acts on NPY/AgRP feeding circuits. Intranasal GHRP-6 activates appetite-regulating neurons in the mouse hypothalamus and increases GH levels (Poelman 2025, PMID 39813130, the most recent verified primary paper). IP GHRP-6 enhanced high-fat-diet intake in ovariectomized rats, with the effect reversed by estradiol (Yokota-Nakagi 2020, PMID 32224927). Antagonist studies using [D-Lys³]-GHRP-6 consistently show that blocking GHS-R1a at hypothalamic sites reduces ghrelin-driven feeding — confirming the agonist circuit.

This appetite signal is the defensible distinguishing feature for GHRP-6 — real, central, dose-dependent, and peer-reviewed. It's not the "more cortisol than other GHRPs" framing some older content claims. See the comparison section.

Older content circulating online frames GHRP-6 as exceptionally cortisol- and prolactin-elevating compared to GHRP-2. The head-to-head literature doesn't support that.

The relevant paper is Arvat et al. Peptides 1997 (PMID 9285939): "Effects of GHRP-2 and hexarelin on GH, prolactin, ACTH and cortisol levels in man." It explicitly describes GHRP-2 and hexarelin as "synthetic, non-natural super-analogs of GHRP-6" with stronger GH-releasing activity than the parent. Prolactin responses across all doses of GHRP-2 or hexarelin were similar between the two super-analogs; ACTH/cortisol-releasing activity was "similar to that of hCRH" — real and measurable, but not exceptional for GHRP-6 specifically. Cheng 1997 (PMID 9096259) confirmed GHRP-2 stimulates GH release from rat pituitary cells via the same receptor and mechanism as GHRP-6.

Peptide	GH Release	Cortisol / Prolactin / ACTH	Hunger
Ipamorelin	Moderate	None at clinical doses	Minimal
GHRP-6 (parent)	Moderate–High	Yes — similar to other GHRPs	Highest of the older GHRPs
GHRP-2 (super-analog)	High	Similar to GHRP-6, possibly more (per PMID 9285939 potency)	Moderate
Hexarelin (super-analog)	Highest	Similar to GHRP-2	Moderate

What the literature does support as GHRP-6 distinctions: strongest appetite signal among the older GHRPs (PMIDs 39813130, 32224927; antagonist literature confirms the circuit), lower GH potency per microgram than the super-analogs, and historical primacy as the parent of the family.

When to choose GHRP-6 vs alternatives

If appetite is a feature (cachexia recovery, recovering from illness, hard-gainers struggling to eat enough) → GHRP-6. If you want a clean GH pulse without HPA-axis activation → Ipamorelin. If you want maximum GH potency → GHRP-2 or Hexarelin. For GHRH synergy → pair any of the GHRPs with Sermorelin, CJC-1295, or Tesamorelin.

No Phase 2 / Phase 3 RCT exists for GHRP-6 as a chronic therapy. The dosing below reflects community and practitioner convention carried over from broader GHRP-class practice — not a trial-derived regimen.

Parameter	Common Range
Dose per injection	100–300 µg SC
Frequency	2–3× per day, fasted
Cycle length	8–16 weeks on, then break (tachyphylaxis emerges with continuous use, well-documented for hexarelin)
Best timing	Morning fasted, pre-/post-workout, before bed (~30 min before sleep on empty stomach)
Route	SC standard; intranasal effective per Frieboes 1999 (PMID 10336729); oral bioavailability is poor

Pairing GHRP-6 with a GHRH analog (CJC-1295 no-DAC, sermorelin, tesamorelin) produces meaningful synergy via the two-pathway convergence (PMIDs 8045963, 8772550). This is the most common stack.

Fasted dosing matters more than most users appreciate. Free fatty acids blunt the GHRP GH response — Peino 1996 (PMID 8772549) showed FFA suppression with acipimox potentiates the GHRP-6 GH response, and Cordido 1996 (PMID 8772550) showed FFA suppression rescues the blunted response in obese subjects. Eating before injection — especially fat — meaningfully reduces the on-target effect.

For a 5 mg vial in 2 mL bacteriostatic water: 2.5 mg/mL, so 1 unit on a U-100 insulin syringe = 25 µg. A 100 µg dose is 4 units, 200 µg is 8 units, 300 µg is 12 units.

Lyophilized vials are stable at room temperature short-term; refrigerate for longer. Reconstituted vials should be refrigerated and used within 28 days. Note that GHRP-6's histidine and tryptophan residues are oxidation-sensitive (Cheng 1995, PMID 8633765) — protect from light and avoid temperature extremes.

For the full reconstitution protocol, see the Bacteriostatic Water guide.

Common acute effects, all anchored in the literature:

• Hunger spike ~20–30 min post-injection — the GHRP-6 signature, real and central (PMID 39813130).
• GH elevation (the on-target effect).
• Stage-2 sleep elevation with evening dosing (Frieboes 1995, PMID 7617137).
• Modest ACTH and cortisol elevation — real and peer-reviewed (PMIDs 7617137, 9285939, 10336729), but similar in magnitude to GHRP-2 and hexarelin, not exceptional within the class.
• Modest prolactin elevation — same caveat.

Less-cited reports from community use (lower PubMed anchor): water retention and mild fluid shifts, injection-site irritation, tingling or numbness in hands, drowsiness with evening dosing, joint stiffness with chronic use, occasional first-week headache.

The "intense hunger" framing is well-supported. The "high cortisol vs other GHRPs" framing in older content is not (PMID 9285939 — these effects exist for GHRP-6 but match magnitudes of GHRP-2 and hexarelin). No Western pharmacovigilance database entries because the molecule has never been approved.

• Pregnancy or breastfeeding — no safety data.
• Active or prior cancer — conservative position for any GH/IGF-axis stimulant.
• Active diabetic retinopathy — class concern for GH elevation (consistent with rhGH labeling).
• Adrenal insufficiency (Addison's, chronic glucocorticoid therapy) — the modest cortisol/ACTH elevation may be relevant; discuss with prescriber.
• Acromegaly or pituitary tumor — absolute.
• Active eating disorder — the strong appetite signal can worsen restrictive or binge patterns.
• Athletes subject to anti-doping testing — do not use. WADA S2.2 names GHRP-6 explicitly; banned at all times.
• Concurrent insulin or sulfonylureas — theoretical hypoglycemia risk via GH counter-regulatory effects.

Ghrelin (the natural hormone). Endogenous 28-residue acylated peptide secreted by gastric P/D1 cells. Same receptor as GHRP-6, structurally unrelated, requires octanoylation at Ser3 for binding. GHRP-6 is the synthetic small-peptide mimetic that predicted ghrelin's existence.

MK-677 (ibutamoren). Non-peptide, orally active GHS-R1a agonist (Patchett 1995, PMID 7624358). Same receptor as GHRP-6 but small-molecule, oral, ~24-hour half-life.

Hexarelin (examorelin). The position-2 D-Trp-methylated GHRP-6 cousin. Higher GH-releasing potency.

Ipamorelin. Pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2). Different scaffold, designed for GHS-R1a selectivity without HPA-axis activation. The cleanest comparator for what GHRP-6 isn't.

GHRP-2 (pralmorelin / KP-102). N-terminus-modified GHRP-6 derivative with higher GH potency. Reached pharma development in Japan as a GH-deficiency diagnostic.

[D-Lys³]-GHRP-6 (the antagonist). Same parent peptide with position-3 Ala swapped for D-Lys, converting the agonist into a competitive GHS-R1a antagonist. Used as a research tool, never therapeutically. If a vendor lists "D-Lys3-GHRP-6" as a product, that's a different molecule with the opposite effect.